The Janssen Pharmaceutical Companies of Johnson & Johnson have announced results from phase 3 clinical trials that show that Tremfya (guselkumab) demonstrated consistent and durable skin clearance. The results, from the phase 3 VOYAGE 1 and VOYAGE 2 clinical trials, were evident in the majority of adult patients with moderate to severe plaque psoriasis over a five-year period.

Tremfya has been approved by the EU to treat adults with moderate to severe plaque psoriasis, and for use alone or in combination with methotrexate to treat adults with active psoriatic arthritis.

For around 125 million people globally, plaque psoriasis can present in a variety of ways, including debilitating physical and psychological symptoms, causing inflamed, scaly skin plaques in addition to the negative impact it can have on patients’ social lives.

Following a separate post-trial analysis of the VOYAGE studies, Tremfya was shown to be highly effective over a five-year period. The data shows that Tremfya can help improve symptoms of moderate to severe plaque psoriasis, thereby improving patients’ quality of life.

The latest data contributes to Janssen’s clinical development programme for Tremfya, which includes the recently launched VISIBLE trial – the first large-scale prospective clinical study dedicated to Black, Hispanic, Indigenous, Asian and other people of colour diagnosed with moderate to severe plaque psoriasis.